REG - Adv Medical Solutns. - Director/PDMR Shareholding

Advanced Medical SolutionsAnnouncement

21/04/2022 17:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220421:nRSU9683Ia&default-theme=true

RNS Number : 9683I  Advanced Medical Solutions Grp PLC  21 April 2022

   21 April 2022

            Advanced Medical Solutions Group plc

("AMS", the "Company" or the "Group")

 

            Director/PDMR Shareholding

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the
world-leading specialist in tissue-healing technologies, announces that on 14
April 2022, the Board, following a recommendation from the Remuneration
Committee, granted new share options ("New Options") to the following
Directors/PDMRs under the existing Advanced Medical Solutions Long Term
Incentive Plan (the 'LTIP'). The vesting of these options is based on
achieving certain performance criteria for the three years prior to vesting.
The performance criteria under the LTIP scheme is split equally between
Earnings Per Share (EPS) growth against fixed targets and Total Shareholder
Return (TSR) against a comparator group. The performance criteria have
remained unchanged for the last eight years. Directors/PDMRs are required to
hold the LTIPs for a period of two years following vesting.

 

 Director/PDMR             Options prior to grant  Options granted  Exercise price of New Options  Vesting Date of New Options  Resultant LTIP holdings
 Chris Meredith            1,032,948               239,552          Nil                            14/04/2025                   1,272,500

 Chief Executive Officer
 Eddie Johnson             258,426                 89,832           Nil                            14/04/2025                   348,258

 Chief Financial Officer

 

Advanced Medical Solutions Group plc also announces that on 14 April 2022,
the Board, following a recommendation from the Remuneration Committee, granted
new share options ("DAB Options") to the following Directors/PDMRs under the
Advanced Medical Solutions Deferred Annual Bonus Plan (the '2014 DAB').

 

This award is in respect of the part of their bonus that the Directors/PDMRs
are compulsorily required to defer for the 2021 financial year. These options
vest at the end of three years. Details of the current DAB holdings of the
Directors following these awards are shown below:

 

 Director/PDMR             Options prior to grant/exercise  Options granted  Exercise price of New Options  Vesting Date of New Options  Resultant holding
 Chris Meredith            34,608                           6,219            303.9 pence                    14/04/2025                   40,827

 Chief Executive Officer
 Eddie Johnson             10,854                           1,883            303.9 pence                    14/04/2025                   12,737

 Chief Financial Officer

 

The information set out below is provided in accordance with the requirements
of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

 

 1.  Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name: Chris Meredith
 2.  Reason for the notification
 a)  Position/status: Chief Executive Officer
 b)  Initial notification/Amendment: Initial Notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name:   Advanced Medical Solutions Group plc
 b)  LEI: 213800HJP6OWOSZI1L74
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument: Ordinary Shares
     of 5p

     Identification code: GB0004536594
 b)  Nature of the transactions:

     1.   Grant of 239,552 options under the Advanced Medical Solutions Long Term
     Incentive Plan on 14 April 2022

     2.   Grant of 6,219 options under the Advanced Medical Solutions Deferred
     Annual Bonus Plan on 14 April 2022
 c)  Price(s) and volume(s):

1.
     Price(s)  Volume(s)
     Nil       239,552

 

     2.

Price(s)     Volume(s)
     303.9 pence  6,219

 

 d)  Aggregated information:

     Aggregated volume: n/a

     Aggregated price: n/a
 e)  Date of the transaction: 14/04/2022
 f)  Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

2.

 Price(s)     Volume(s)
 303.9 pence  6,219

 

 

d)

Aggregated information:

Aggregated volume: n/a

Aggregated price: n/a

e)

Date of the transaction: 14/04/2022

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

 

 1.  Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name: Eddie Johnson
 2.  Reason for the notification
 a)  Position/status: Chief Financial Officer
 b)  Initial notification/Amendment: Initial Notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name:   Advanced Medical Solutions Group plc
 b)  LEI: 213800HJP6OWOSZI1L74
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument: Ordinary Shares
     of 5p

     Identification code: GB0004536594
 b)  Nature of the transactions:

     3.   Grant of options under the Advanced Medical Solutions Long Term
     Incentive Plan on 14 April 2022

     4.   Grant of options under the Advanced Medical Solutions Deferred Annual
     Bonus Plan on 14 April 2022
 c)  Price(s) and volume(s):

2.
     Price(s)  Volume(s)
     Nil       89,832

 

     2.

Price(s)     Volume(s)
     303.9 pence  1,833

 

 d)  Aggregated information:

     Aggregated volume: n/a

     Aggregated price: n/a
 e)  Date of the transaction: 14/04/2022
 f)  Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

2.

 Price(s)     Volume(s)
 303.9 pence  1,833

 

 

 

d)

Aggregated information:

Aggregated volume: n/a

Aggregated price: n/a

e)

Date of the transaction: 14/04/2022

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

-End -

 

 

 

 

 

 

 

For further information, please visit www.admedsol.com
(http://www.admedsol.com) or contact:

 

 Advanced Medical Solutions Group plc             Tel: +44 (0) 1606 545508
 Chris Meredith, Chief Executive Officer

 Eddie Johnson, Chief Financial Officer

 Consilium Strategic Communications               Tel: +44 (0) 20 3709 5700
 Mary-Jane Elliott / Matthew Neal / Matthew Cole  AMS@consilium-comms.com

 Investec Bank PLC (NOMAD & Broker)               Tel: +44 (0) 20 7597 5970
 Daniel Adams / Gary Clarence

 HSBC Bank PLC (Broker)                           Tel: 44 (0) 20 7991 8888
 Sam McLennan / Joe Weaving / Stephanie Cornish

 

About Advanced Medical Solutions Group plc - see www.admedsol.com
(http://www.admedsol.com)

AMS is a world-leading independent developer and manufacturer of innovative
tissue-healing technology, focused on quality outcomes for patients and value
for payers. AMS has a wide range of surgical products including tissue
adhesives, sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand(®), RESORBA(®),
LiquiBandFix8(®) and Seal-G(®). AMS also supplies wound care dressings such
as silver alginates, alginates and foams through its ActivHeal(®) brand as
well as under white label. Since 2019, the Group has made three acquisitions:
Sealantis, an Israeli medical device company with a patent-protected sealant
technology platform; Biomatlante, an established French developer and
manufacturer of innovative surgical biomaterial technologies and Raleigh, a UK
leading coater and converter of materials predominately for woundcare and
bio-diagnostics products.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the
Czech Republic and Israel, are sold globally via a network of multinational or
regional partners and distributors, as well as via AMS's own direct sales
forces in the UK, Germany, the Czech Republic and Russia. The Group has
R&D innovation hubs in the UK, Germany, France and Israel. Established in
1991, the Group has more than 700 employees. For more information, please
see www.admedsol.com (http://www.admedsol.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBLGDSRDDDGDB